Stockscreener 앱 받기
1.24
8.15%
-0.11
시간 외 거래:
1.25
0.01
+0.81%
Maxcyte Inc 주식(MXCT)의 최신 뉴스
MaxCyte (MXCT) The 44th Annual William Blair Growth Stock Conference Summary - Quartr
MaxCyte to report Q2 2026 financial results on August 12 - scanx.trade
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 - The Manila Times
Enterprise value to revenue forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
Price to sales forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
Price to earnings forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
MaxCyte Inc focuses on cell engineering. Nasdaq-listed MXCT targets long-term growth - ad-hoc-news.de
MaxCyte (MXCT) Stephens Annual Investment Conference Summary - Quartr
Enterprise value to EBITDA forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MaxCyte stock leans on platform demand. Nasdaq listing stays central. - ad-hoc-news.de
Price to sales forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Enterprise value to revenue forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Price to book forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MYE0 Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT) - TradingView
MXCT Forecast — Price Target — Prediction for 2027 - TradingView
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte Inc (MXCT) Institutional Confidence - TradingKey
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
Form 4 MaxCyte Inc For: 22 June By Investing.com - Investing.com South Africa
MaxCyte (MXCT) grants RSUs and stock options to director - Stock Titan
MaxCyte (MXCT) director awarded RSUs and stock options in annual grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and options in annual equity grant - Stock Titan
MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award - Stock Titan
MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant - Stock Titan
MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants - Stock Titan
MaxCyte (MXCT) director receives RSU and stock option grant - Stock Titan
MXCT Q1 2026 Earnings: Strong EPS Beat Drives Share Price HigherOne-Time Loss Impact - dars.gov.et
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
MaxCyte Stockchart levels and volatility on a quiet news day - Ad-hoc-news.de
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026 - Minichart
MaxCyte shareholders elect directors and approve auditor at annual meeting - Investing.com
MaxCyte shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com Nigeria
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MaxCyte Inc (MXCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MaxCyte Shareholders Reelect Directors and Ratify Auditor - TipRanks
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MaxCyte Inc (MXCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery - The Globe and Mail
MaxCyte (NASDAQ: MXCT) investors reelect board and ratify auditor - Stock Titan
MaxCyte regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Canada
MaxCyte regains compliance with Nasdaq minimum bid price rule - Investing.com
MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
MaxCyte (NASDAQ: MXCT) restores Nasdaq minimum bid-price compliance after warning - Stock Titan
MXCT Q1 2026 Earnings: Strong EPS Beat Drives Positive Stock ReactionPre-Earnings Drift - DonanımHaber
MaxCyte Inc. (MXCT) Q1 2026 Earnings: EPS Surges Past Estimates Despite Revenue Disclosures Left UnclearAnnual Report - DonanımHaber
MXCT Q1 2026 Earnings: EPS Beats Estimates by Wide Margin, But Revenue Details WithheldConsensus Forecast Report - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and MaxCyte (MXCT) - The Globe and Mail
MXCT Q1 2026 Earnings: EPS Surprises Strongly to the Upside, Beating Estimates by 50.98%Revenue Inflection Point - newsline.com
MaxCyte Inc. (MXCT) Posts 3.4% Gain, Testing Resistance at $1.27Entry Point Alerts - newsline.com
MaxCyte (MXCT) Edges Higher on Increased Activity, Tests Key Resistance at $1.27Stop Hunt - The Legal Advocate
2.81%
자본화:
|
볼륨(24시간):